Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
IRVINE, Calif. - Edwards Lifesciences Corporation (NYSE: EW), a $44.2 billion medical device company with an impressive 79.5% gross profit margin, has received approval from the U.S. Food and Drug Administration (FDA) for its SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform to be used in patients with severe aortic stenosis (AS) who do not yet show symptoms. According to InvestingPro analysis, the company is currently trading near its Fair Value, with 14 analysts recently revising their earnings estimates upward. This marks the first time the FDA has endorsed a TAVR therapy for asymptomatic individuals with this condition.
The decision by the FDA is underpinned by results from the EARLY TAVR trial, which indicated that patients with severe AS who received the TAVR treatment had better outcomes than those under clinical surveillance, a protocol that traditionally involves watchful waiting until symptoms manifest. The EARLY TAVR trial was a pivotal study that compared TAVR directly to watchful waiting in patients with asymptomatic severe AS. According to the trial, with a median follow-up of 3.8 years, 26.8% of patients in the TAVR group faced death, stroke, or unplanned cardiovascular hospitalization, versus 45.3% in the surveillance group. These findings were published in The New England Journal of Medicine. The company’s strong financial position, with moderate debt levels and sufficient cash flows to cover interest payments according to InvestingPro data, positions it well to continue advancing its innovative medical solutions. InvestingPro subscribers can access 10+ additional exclusive insights about Edwards Lifesciences’ financial health and market position.
Dr. Philippe Genereux, director of the structural heart program at Gagnon Cardiovascular Institute, highlighted the urgency in reevaluating current TAVR guidelines and practice due to the unpredictable nature of symptom onset in severe AS patients. He emphasized the importance of early evaluation by a heart team to improve patient outcomes and healthcare system efficiency.
Larry Wood, Edwards’ corporate vice president, expressed the company’s pride in advancing the understanding of this life-threatening disease through high-quality science and in optimizing treatment for patients. The SAPIEN 3 platform, including SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA, has been used to treat over 1 million patients globally and is considered the most studied valve platform with unmatched clinical outcomes.
Edwards Lifesciences is recognized as a leading company in structural heart innovations, committed to improving patient lives through advanced technologies and partnerships with healthcare stakeholders. With annual revenue of $5.52 billion and consistently strong financial health metrics, the company maintains its market leadership position. For detailed analysis and comprehensive insights, including the company’s extensive Pro Research Report, visit InvestingPro.
The information in this article is based on a press release statement from Edwards Lifesciences.
In other recent news, Edwards Lifesciences reported a robust first quarter for 2025, with earnings per share (EPS) reaching $0.64, surpassing analysts’ expectations of $0.60. The company’s revenue also exceeded forecasts, totaling $1.41 billion compared to the anticipated $1.4 billion. This performance led Edwards Lifesciences to raise its 2025 sales guidance to a range of $5.7 billion to $6.1 billion. Piper Sandler analysts upgraded Edwards Lifesciences stock from Neutral to Overweight, citing confidence in the company’s growth prospects and raising the price target to $80.00. This optimism is supported by strong performance in the Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments. Stifel analysts also maintained a Buy rating for the company, with a price target of $90.00, highlighting anticipated advancements in TAVR and potential FDA approval for the EARLY TAVR label expansion. Edwards Lifesciences’ management remains optimistic about the company’s strategic positioning and growth potential amid a challenging macroeconomic environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.